Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.50 |
| ▸ | ESRRB | O95718 | 1/20 | 0.49 |
| ▸ | ESRRG | P62508 | 1/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4614694 | 0.81 | EPHX2 (0.81) | LTA4HEPHX2HDAC1HDAC8TP53 | |
| SCHEMBL30899988 | 0.81 | L3MBTL1 (0.67) | LTA4HEPHX2HDAC1HDAC8TP53 | |
| SCHEMBL2511779 | 0.79 | GLA (0.43) | LTA4HEPHX2CDK1CNR2NLRP3 | |
| SCHEMBL714137 | 0.79 | HDAC1 (0.63) | LTA4HEPHX2HDAC1HDAC8CNR2 | |
| SCHEMBL21357567 | 0.79 | TRPV1 (0.58) | ESRRBESRRGLMNA | |
| SCHEMBL8425193 | 0.78 | BACE1 (0.54) | LTA4HEPHX2HDAC1HDAC8TP53 | |
| SCHEMBL28499154 | 0.78 | ALDH1A1 (0.69) | LTA4HEPHX2HDAC1HDAC8CNR2 | |
| SCHEMBL2511687 | 0.77 | HPGD (0.47) | HDAC1CNR2LMNA | |
| SCHEMBL7241146 | 0.77 | GAA (0.60) | EPHX2SMN1; SMN2 | |
| SCHEMBL8566065 | 0.77 | HDAC1 (0.61) | LTA4HEPHX2HDAC1HDAC8CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996198-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | Kalypsys, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109577-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109577-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | KALYPSYS, INC (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219193-A1 | ALKYLAMINE-SUBSTITUTED BICYCLIC ARYL COMPOUNDS USEFUL AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | LTA4H 1678/4885EPHX2 3603/4885HDAC1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.